---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-032804"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:08:14.203577+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics appoints Anil Singhal to Board; Derek DiRocco to resign at 2025 annual meeting

## Summary
- Derek DiRocco, M.D. resigns from Board, effective at 2025 annual meeting; no disagreement cited.
- Anil Singhal, Ph.D. appointed as Class I director, effective Feb 19, 2025; joins Audit Committee.
- Dr. Singhal has >30 years biopharma R&D experience; currently President & CEO of Trishula Therapeutics.
- Dr. Singhal receives annual cash comp of $40,000 + $7,500 for Audit Committee; option for 45,000 shares at $1.40, vesting over 3 years.

## SEC filing metadata
- accession: 0001193125-25-032804
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312525032804/0001193125-25-032804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312525032804/d935677d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-032804
- JSON: https://secwatch.observer/filing/0001193125-25-032804.json
- Plain text: https://secwatch.observer/filing/0001193125-25-032804.txt

## Key facts
- Executive change
  Derek DiRocco, M.D. resigned as Director at Werewolf Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000119312525032804/0001193125-25-032804-index.htm
- Executive change
  Anil Singhal, Ph.D. was appointed as Director at Werewolf Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000119312525032804/0001193125-25-032804-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.